TransCode Therapeutics, Inc. Announces Closing of Registered Direct Offering

Company Overview - TransCode Therapeutics, Inc. is a clinical-stage oncology company focused on treating metastatic disease through RNA therapeutics [5] - The company's lead therapeutic candidate, TTX-MC138, targets metastatic tumors that overexpress microRNA-10b, a biomarker of metastasis [5] - TransCode has a portfolio of first-in-class RNA therapeutic candidates designed to improve RNA delivery and access novel genetic targets for cancer treatment [5] Recent Offering - The company announced the closing of a sale of 10,250,000 shares of common stock and warrants, generating gross proceeds of approximately $10 million at a price of $0.98 per share [1][2] - Proceeds from the offering will primarily be used for product development activities, including clinical trials for TTX-MC138 and general corporate purposes [2] - ThinkEquity acted as the sole placement agent for the offering [2] Regulatory Compliance - The offering was conducted under an effective shelf registration statement filed with the U.S. Securities and Exchange Commission (SEC) [3] - The final prospectus supplement related to the offering is available on the SEC's website [3]